The contemporary medical and pharmaceutical sectors operate within an intensely policed regulatory environment shaped by public health crises and advanced technological surveillance. Within this structural framework, the traditional patient-prescriber-pharmacist relationship is no longer a localized clinical interaction. Instead, it is integrated into a multi-jurisdictional database ecosystem known as Prescription Drug Monitoring Programs (PDMPs). Far from […]